Psychiatric-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: A phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe

Attention Deficit ◽

Phase 3 ◽

Double Blind ◽

Hyperactivity Disorder ◽

Parallel Group ◽

Safety Outcomes

EPA-0685 – Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): phase 3, randomized, double-blind, multicenter, placebo- and active-reference study

European Psychiatry ◽

10.1016/s0924-9338(14)78052-6 ◽

2014 ◽

Vol 29 ◽

pp. 1 ◽

Cited By ~ 2

Author(s):

A. Hervas ◽

M. Huss ◽

M. Johnson ◽

F. McNicholas ◽

J. Van Stralen ◽

...

Keyword(s):

Attention Deficit ◽

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976565.793485491 ◽

2013 ◽

Author(s):

Philip Asherson

Keyword(s):

Attention Deficit ◽

Phase 3 ◽

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2012.11.012 ◽

2013 ◽

Vol 23 (10) ◽

pp. 1208-1218 ◽

Cited By ~ 71

Author(s):

David Coghill ◽

Tobias Banaschewski ◽

Michel Lecendreux ◽

Cesar Soutullo ◽

Mats Johnson ◽

...

Keyword(s):

Attention Deficit ◽

Phase 3 ◽

Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate

European Child & Adolescent Psychiatry ◽

10.1007/s00787-015-0718-0 ◽

2015 ◽

Vol 25 (2) ◽

pp. 141-149 ◽

Cited By ~ 13

Author(s):

Peter Nagy ◽

Alexander Häge ◽

David R. Coghill ◽

Beatriz Caballero ◽

Ben Adeyi ◽

...

Keyword(s):

Attention Deficit ◽

Functional Outcomes ◽

Inadequate Response ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

Clinical Therapeutics ◽

10.1016/s0149-2918(07)80083-x ◽

2007 ◽

Vol 29 (3) ◽

pp. 450-463 ◽

Cited By ~ 153

Author(s):

Joseph Biederman ◽

Suma Krishnan ◽

Yuxin Zhang ◽

James J. McGough ◽

Robert L. Findling

Keyword(s):

Attention Deficit ◽

Phase Iii ◽

Double Blind ◽

Hyperactivity Disorder ◽

Parallel Group Study ◽

Parallel Group

Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

CNS Drugs ◽

10.1007/s40263-014-0188-9 ◽

2014 ◽

Vol 28 (11) ◽

pp. 1059-1069 ◽

Cited By ~ 14

Author(s):

Ralf W. Dittmann ◽

Esther Cardo ◽

Peter Nagy ◽

Colleen S. Anderson ◽

Ben Adeyi ◽

...

Keyword(s):

Treatment Response ◽

Attention Deficit ◽

Double Blind ◽

Weight-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with ADHD: Post-hoc analysis from a phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe

Neuropsychiatrie de l Enfance et de l Adolescence ◽

10.1016/j.neurenf.2012.04.686 ◽

2012 ◽

Vol 60 (5) ◽

pp. S263

Author(s):

A. Zuddas ◽

D.R. Coghill ◽

T. Banaschewski ◽

C. Soutullo ◽

A. Lynes ◽

...

Keyword(s):

Phase 3 ◽

Double Blind ◽

Post Hoc Analysis ◽

Parallel Group ◽

Safety Outcomes ◽

Post Hoc

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

CNS Drugs ◽

10.1007/s40263-013-0104-8 ◽

2013 ◽

Vol 27 (12) ◽

pp. 1081-1092 ◽

Cited By ~ 53

Author(s):

Ralf W. Dittmann ◽

Esther Cardo ◽

Peter Nagy ◽

Colleen S. Anderson ◽

Ralph Bloomfield ◽

...

Keyword(s):

Attention Deficit ◽

Efficacy And Safety ◽

Double Blind ◽

Hyperactivity Disorder ◽

Phase Iiib

Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents

Archives of Clinical Psychiatry (São Paulo) ◽

10.1590/0101-60830000000007 ◽

2014 ◽

Vol 41 (2) ◽

pp. 34-39 ◽

Cited By ~ 2

Author(s):

Paulo Mattos

Keyword(s):

Attention Deficit ◽

Efficacy And Safety ◽

A Double-blind Comparison of Desipramine and Placebo in Children and Adolescents With Chronic Tic Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder

Archives of General Psychiatry ◽

10.1001/archpsyc.59.7.649 ◽

2002 ◽

Vol 59 (7) ◽

pp. 649 ◽

Cited By ~ 78

Author(s):

Thomas Spencer ◽

Joseph Biederman ◽

Barbara Coffey ◽

Daniel Geller ◽

Margaret Crawford ◽

...

Keyword(s):

Attention Deficit ◽

Double Blind ◽

Tic Disorder ◽

Hyperactivity Disorder ◽

Chronic Tic Disorder ◽

Blind Comparison